Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Depreciation & Amortization (CF) (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $72000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Depreciation & Amortization (CF) fell 22.58% year-over-year to $72000.0, compared with a TTM value of $292000.0 through Dec 2023, down 39.67%, and an annual FY2024 reading of $319000.0, up 9.25% over the prior year.
  • Depreciation & Amortization (CF) was $72000.0 for Q4 2023 at Terns Pharmaceuticals, roughly flat from $72000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $172000.0 in Q1 2021 and bottomed at $72000.0 in Q2 2023.
  • Average Depreciation & Amortization (CF) over 4 years is $105125.0, with a median of $103500.0 recorded in 2020.
  • The sharpest move saw Depreciation & Amortization (CF) surged 95.45% in 2021, then plummeted 47.83% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $106000.0 in 2020, then rose by 7.55% to $114000.0 in 2021, then decreased by 18.42% to $93000.0 in 2022, then fell by 22.58% to $72000.0 in 2023.
  • Business Quant data shows Depreciation & Amortization (CF) for TERN at $72000.0 in Q4 2023, $72000.0 in Q3 2023, and $72000.0 in Q2 2023.